Acorda Therapeutics, Inc. (NASDAQ:ACOR) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

A number of other analysts have also commented on ACOR. CIBC began coverage on shares of Acorda Therapeutics in a research note on Thursday, November 9th. They issued a “market perform” rating for the company. HC Wainwright began coverage on shares of Acorda Therapeutics in a research note on Wednesday, November 8th. They issued a “buy” rating and a $35.00 price target for the company. Oppenheimer Holdings, Inc. began coverage on shares of Acorda Therapeutics in a research note on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price target for the company. Cantor Fitzgerald reiterated a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a research note on Thursday, September 28th. Finally, Jefferies Group LLC lifted their price target on shares of Acorda Therapeutics from $22.00 to $25.00 and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $23.63.

Shares of Acorda Therapeutics (ACOR) traded down $11.20 during mid-day trading on Wednesday, hitting $17.00. 9,866,800 shares of the stock were exchanged, compared to its average volume of 933,632. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The company had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. The business’s revenue was up 4.0% compared to the same quarter last year. equities research analysts anticipate that Acorda Therapeutics will post -0.48 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Acorda Therapeutics, Inc. (ACOR) to Sell” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/15/valuengine-downgrades-acorda-therapeutics-inc-acor-to-sell.html.

In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp acquired 766,201 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The shares were bought at an average price of $19.23 per share, with a total value of $14,734,045.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.90% of the company’s stock.

A number of large investors have recently modified their holdings of ACOR. Legal & General Group Plc lifted its holdings in Acorda Therapeutics by 1.4% during the first quarter. Legal & General Group Plc now owns 81,165 shares of the biopharmaceutical company’s stock valued at $1,727,000 after purchasing an additional 1,127 shares in the last quarter. Thrivent Financial For Lutherans lifted its holdings in Acorda Therapeutics by 4.6% during the first quarter. Thrivent Financial For Lutherans now owns 25,900 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 1,130 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Acorda Therapeutics by 6.0% during the first quarter. Vanguard Group Inc. now owns 4,139,589 shares of the biopharmaceutical company’s stock valued at $86,931,000 after purchasing an additional 233,575 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Acorda Therapeutics by 8.1% during the first quarter. Geode Capital Management LLC now owns 440,824 shares of the biopharmaceutical company’s stock valued at $9,256,000 after purchasing an additional 33,030 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Acorda Therapeutics by 21.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,831,450 shares of the biopharmaceutical company’s stock valued at $38,474,000 after purchasing an additional 323,888 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.